Hyperparathyroidism in Keeshond (Dog) — Management Guide

Comprehensive guide to primary hyperparathyroidism in Keeshonds: causes, signs of hypercalcemia, diagnostic testing, ethanol ablation and parathyroidectomy, and post-op hypocalcemia monitoring.

Quick Overview

• What it is: Primary hyperparathyroidism (PHPTH) is an uncommon endocrine disorder in dogs where one (or more) parathyroid glands develop an autonomous lesion (typically an adenoma) that overproduces parathyroid hormone (PTH), causing hypercalcemia.
• Who’s at risk: Middle-aged to older dogs; Keeshonds have been reported in case series as predisposed. Both sexes affected; solitary adenomas are most common.
• Prognosis: Excellent with definitive treatment (surgical parathyroidectomy or percutaneous ethanol ablation) for solitary adenomas; long-term monitoring required. Major short-term risk is post-operative hypocalcemia, which is usually transient and manageable.

Pathophysiology — explained simply

Parathyroid glands sense blood ionized calcium and secrete PTH to maintain calcium balance. In primary hyperparathyroidism an intrinsic lesion (most commonly a parathyroid adenoma, less commonly hyperplasia or carcinoma) secretes PTH regardless of blood calcium level. High PTH increases bone resorption, increases calcium reabsorption from the kidney, and increases activation of vitamin D to raise intestinal calcium absorption — all leading to hypercalcemia. Chronically elevated calcium affects many systems: kidneys, GI tract, musculoskeletal and nervous systems.

Breed-specific risk factors and prevalence (Keeshond focus)

• Primary hyperparathyroidism is uncommon overall in dogs but has been reported across many breeds.
• Keeshonds appear in multiple referral case series as one of the breeds over-represented for primary hyperparathyroidism, suggesting a possible breed predisposition. However, prevalence remains low; most Keeshonds will never develop this disease.
• Typical signalment: middle-aged to older (median ages reported around 8–11 years). No absolute sex predilection.

Clinical signs and stages

Signs are primarily from hypercalcemia and are often nonspecific:

• Early/subtle: mild polyuria/polydipsia, decreased appetite, lethargy
• GI: vomiting, constipation
• Renal: increased thirst, increased urination, predisposition to urinary tract infection and nephroliths
• Neuromuscular: weakness, muscle wasting
• Severe: dehydration, anorexia, collapse, seizures (rare)

Diagnostic approach

Goals: confirm true hypercalcemia, determine whether it’s PTH-driven (primary hyperparathyroidism) and locate the lesion if present.

Key tests summary: ionized Ca, intact PTH, PTHrP, serum biochemistry, cervical ultrasound.

Treatment options

Aim: normalize calcium, address the underlying cause (ablate/remove the parathyroid lesion), and manage complications.

A. Emergency/medical stabilization of severe hypercalcemia

• IV crystalloid diuresis (0.9% NaCl) to correct dehydration and promote calciuresis.
• Furosemide (loop diuretic) after rehydration to increase urinary calcium excretion (typical dose concept: 1–4 mg/kg IV/SC q6–12h; adjust per status). Avoid thiazides.
• Bisphosphonates for longer-term reduction of bone-derived calcium: pamidronate or zoledronate are commonly used in veterinary practice. Pamidronate dosing commonly reported 1–2 mg/kg IV over 2–4 hours; zoledronate dosing commonly 0.025–0.1 mg/kg IV over 15–30 minutes in referral settings. Bisphosphonates act over days and can last weeks.
• Prednisone can be used where appropriate (e.g., 0.5–2 mg/kg/day) but is less effective for PTH-driven hypercalcemia than for vitamin D or malignancy-related causes.
• Calcitonin (short-lived effect) can lower calcium rapidly for a few hours — used rarely because of tachyphylaxis.

B. Definitive treatments — remove or destroy the PTH-secreting tissue

1) Surgical parathyroidectomy (standard of care for many cases)

• Procedure: ventral cervical exploration and excision of the affected parathyroid gland(s). Performed by or in consultation with a board-certified surgeon (ACVS) or experienced general surgeon.
• Success: reported cure rates are high for solitary adenomas — commonly cited >90% when a single adenoma is removed and no carcinoma/metastasis exists. Recurrence is uncommon for true solitary adenomas.
• Risks: anesthesia risks, hemorrhage, damage to recurrent laryngeal nerve, transient or prolonged hypocalcemia.
• Peri-operative planning: stabilize hypercalcemia pre-op; plan for intensive post-op ionized calcium monitoring.

• Technique: under ultrasound guidance, a small-gauge needle is placed into the parathyroid lesion and 95% ethanol (small volume) is injected to chemically ablate the adenoma.
• When used: often chosen for small, well-localized solitary adenomas in patients where general anesthesia or surgery is higher risk, or when owners prefer a minimally invasive approach.
• Success rates: variable across studies. Reported immediate success rates often in the 70–90% range for selected solitary lesions; recurrence rates may be higher than surgery in some series. Multiple treatments may be required. Success depends on accurate localization and operator experience.
• Complications: local tissue necrosis, damage to adjacent structures (recurrent laryngeal nerve), hemorrhage, post-ablation hypocalcemia.
• Requires experienced ultrasonographer/interventional radiologist.

• Cryoablation or radiofrequency ablation are described in isolated reports but are less commonly used than ethanol ablation or surgery.
• Medical management (long-term) with bisphosphonates and oral medications may be chosen in high anesthetic-risk patients but does not cure the underlying lesion; useful as palliative management.

Post-operative hypocalcemia — monitoring and treatment

Why it happens: After removal/ablation of the PTH-secreting tissue, the suppressed normal parathyroid tissue can take days to recover, and bone uptake of calcium can transiently exceed blood calcium (hungry bone syndrome), leading to hypocalcemia.

Monitoring

• Measure ionized calcium (preferred) frequently after definitive treatment: commonly q6–12 hours for the first 24–48 hours, then daily while inpatient. Many practices monitor for at least 48–72 hours after surgery or ablation because clinically significant drops often occur within this window.
• Watch for clinical signs of hypocalcemia: facial rubbing, pawing at the mouth, muscle tremors, restlessness, stiffness, ataxia, seizures.

• Mild, asymptomatic decreases: start oral calcium supplementation and calcitriol proactively for patients at high risk (many clinicians use this strategy when pre-op PTH was very high or bones show increased uptake).
• Oral calcium: calcium carbonate is commonly used. Dosing concept: give elemental calcium to effect — a commonly used range is 20–75 mg/kg/day of elemental calcium divided q8–12h (exact dosing depends on product and patient; calculate elemental calcium from formulation).
• Calcitriol (active vitamin D): helps intestinal calcium absorption and reduces dependence on PTH. Typical starting dosing concepts: 2.5–10 ng/kg PO q12–24h (start low and adjust based on serum ionized calcium and under veterinary guidance). Calcitriol has a long effect and requires monitoring to avoid hypercalcemia.
• Symptomatic or severe hypocalcemia (tetany, seizures, severe weakness): treat with IV calcium gluconate 10% — slow infusion (e.g., 0.5–1.0 mL/kg slowly over 10–20 minutes with ECG monitoring; then repeated or CRI if needed). Hospitalize and monitor ECG during IV calcium administration.

• Many dogs need calcium/calcitriol for days to weeks; some for a few months; permanent supplementation is uncommon but possible in rare cases. Taper when ionized calcium is stable in the normal range over several days to weeks, under veterinary guidance.

Long-term management and monitoring

• Recheck schedule: first rechecks commonly at 1–2 weeks, 4–6 weeks, then every 3–6 months for a year, then annually if stable. Monitor ionized calcium, renal values (BUN/creatinine), and clinical signs.
• Monitor for recurrence: if the lesion was not fully ablated or if hyperplasia/carcinoma was present, hypercalcemia may recur; recurrence necessitates re-evaluation (repeat ultrasound, PTH measurement) and possible additional treatment.
• Dental and urinary care: hypercalcemia predisposes to urinary tract infections and stones; monitor urine and consider imaging if recurrent UTIs or hematuria occur.
• Medication side-effect monitoring: if on bisphosphonates, monitor renal values; if on calcitriol, monitor for hypercalcemia.

Prognosis and quality of life

• With successful removal or ablation of a solitary adenoma, prognosis is generally excellent and quality of life usually returns to normal once calcium normalizes.
• Short-term risks: peri-operative complications and transient hypocalcemia (commonly reported in studies in roughly 20–40% of cases depending on criteria) but often manageable.
• Long-term outcomes are favorable when diagnosis and treatment are timely and appropriate monitoring is performed.

Living with hyperparathyroidism — practical daily tips

• Hydration: encourage regular access to fresh water; dehydration worsens hypercalcemia.
• Diet: avoid unnecessary vitamin D or calcium supplements unless prescribed. Discuss diet with your vet — no single diet cures hyperparathyroidism, but avoid diets with excessive calcium or vitamin D if your vet recommends.
• Medication adherence: if on oral calcium or calcitriol post-op, give exactly as prescribed; do not stop suddenly without veterinary advice.
• Watch for signs: monitor appetite, drinking/urination, energy level, vomiting, constipation, or tremors and report changes promptly.
• Record keeping: keep a notebook of calcium results and medication doses — helpful for long-term monitoring.

When to see your vet urgently

Seek immediate veterinary attention if your dog develops:

• New or worsening vomiting, severe lethargy, collapse
• Seizures, tremors, severe weakness, or difficulty breathing
• Rapidly increased thirst and urination combined with disorientation
• After surgery/ablation: signs of hypocalcemia (facial rubbing, pawing at the mouth, tremors) or collapse

Specialist referral

• Consider referral to a board-certified veterinary internal medicine specialist (ACVIM) or surgeon (ACVS) for complex diagnostic cases, for planning parathyroidectomy, or for ultrasound-guided ethanol ablation performed by experienced interventional radiologists.

Evidence, success rates and caveats

• Surgical parathyroidectomy: high success for solitary adenomas; cure rates frequently reported >90% in referral studies when lesion is solitary and resection is complete.
• Percutaneous ethanol ablation: minimally invasive alternative with reported immediate success rates often in the 70–90% range in selected cases; recurrence and need for repeat procedures may be higher than with surgery.
• Post-op hypocalcemia: transient hypocalcemia is a common complication (frequency varies by series), but rescue treatment is straightforward in most cases when monitoring is appropriate.

Key takeaways

• Primary hyperparathyroidism is an uncommon but treatable cause of hypercalcemia in dogs.
• Confirm with ionized calcium and intact PTH measurements and localize the lesion with cervical ultrasound when possible.
• Definitive therapy is parathyroidectomy or ultrasound-guided ethanol ablation for suitable solitary lesions; both options require experienced clinicians.
• Monitor ionized calcium frequently after treatment and be prepared to treat hypocalcemia.
• Prognosis is excellent in most dogs after successful treatment, but long-term monitoring is necessary.

This guide is for educational purposes. Always consult your veterinarian for diagnosis and treatment.

References and further reading

• American College of Veterinary Internal Medicine (ACVIM) — www.acvim.org
• Selected peer-reviewed literature and case series in the Journal of Veterinary Internal Medicine (JVIM) and JAVMA on primary hyperparathyroidism and ethanol ablation techniques.
• Plumb’s Veterinary Drug Handbook — for dosing references and drug-specific details.

Frequently Asked Questions